When are we getting more Covid-19 vaccine data? Is CRISPR having a dot-com moment? And how to separate disinformation from healthy dissent?
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss the implications of Johnson & Johnson’s any-day-now data on a one-shot vaccine for Covid-19. Then, Kevin Davies, executive editor of the CRISPR Journal, joins us to talk about the strange boom in genome editing stocks and the future of the revolutionary technology. Finally, we talk to Megan Ranney, an emergency room physician and Brown University professor, about the challenges of Covid-19 science communication in a post-Trump world.
For more on what we cover, here’s the latest from J&J; here’s where you can find Davies’s CRISPR book; and here’s our complete coverage of the coronavirus pandemic.
Be sure to sign up on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].